Fitzgerald Newsletter

Get news you can use in the latest Fitzgerald Newsletter

November 2021

Gender Diverse Individuals and Clinical Preventive Services: Addressing Access to Treatment and Healthcare Experiences of LGBTQIA+ People

There are more than 11 million individuals in the United States who identify as lesbian, gay, bisexual, transgender, queer, intersex, or asexual—a group NIH identifies as a “health disparity population.” Recent guidance from the US Preventive Services Task Force and the Kaiser Family Foundation will help healthcare providers better understand the healthcare needs of this population and address barriers to their care. Read More

Certification Q&A: Top Diagnoses in Primary Care Offices

Using data from national surveys of primary care office visits, Dr. Fitzgerald presents the top 20 diagnoses to learn evaluation, diagnosis, and treatment of, so that you can be prepared for the family or the adult-gerontology-primary care NP certification exams. Read More

NEWS BRIEFS

Shingrix for Immunocompromised Adults Ages 19+

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend two doses of Zoster Vaccine Recombinant (Shingrix) for the prevention of shingles and its complications in adults 19 years of age and older who are or will be immunodeficient or immunosuppressed due to disease or therapy. Read More

Pneumococcal Vax Guideline Update

ACIP voted in favor of updates to the pneumococcal vaccination recommendations for certain adults 65 years of age and older and for adults 19 to 64 years of age with certain underlying health conditions or other disease risk factors. Read More

Hepatitis B Virus/Ebola/Smallpox, Monkeypox Immunizations

ACIP updated its recommendations for hepatitis B virus, ebola, smallpox, and monkeypox immunizations. Read More

Younger Patients Now Indicated for Asthma Drug

The FDA expanded the indications for dupilumab (Dupixent) to include add-on maintenance treatment of patients 6 to 11 years of age with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticoid-dependent asthma. Read More

First Liquid Topiramate Formulation Approved for Seizure Indication

The FDA authorized the first ready-to-use liquid formulation of topiramate (Eprontia oral solution) for partial-onset, primary generalized tonic-clonic seizures. Read More

COVID-19 News